You are here

Blood Journal-Long-term prognostic significance of early molecular response to imatinib

sandy craine's picture
Submitted by sandy craine on Wed, 25/08/2010 - 7:45pm

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an analysis from the international randomized study of interferon versus STI571 (IRIS)

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an analysis from the international randomized study of interferon versus STI571 (IRIS)

Haematology Times- EHA role of Patient Advocacy

sandy craine's picture
Submitted by sandy craine on Mon, 26/07/2010 - 12:17pm

 

Patient advocacy in clinical trials- EHA Congress, June 10-13th, 2010, Barcelona—Though recent developments aim to improve the clinical trial process, a group of experts says much more work is necessary. 

 

Patient advocacy in clinical trials- EHA Congress, June 10-13th, 2010, Barcelona—Though recent developments aim to improve the clinical trial process, a group of experts says much more work is necessary. 

Discovery suggests possible treatment strategy for aggressive leukemias

sandy craine's picture
Submitted by sandy craine on Tue, 20/07/2010 - 3:01pm

 

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia (CML).

 

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia (CML).

Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients

sandy craine's picture
Submitted by sandy craine on Mon, 28/06/2010 - 8:56pm
Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients Elsevier Global Medical News. 2010 Jun 21, N Osterweil

Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients
Elsevier Global Medical News. 2010 Jun 21, N Osterweil

Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis

sandy craine's picture
Submitted by sandy craine on Tue, 08/06/2010 - 6:39pm
Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis Haefaa Alchalby1, Anita Badbaran1, Tatjana Zabelina1, Guido Kobbe2, Joachim Hahn3, Daniel Wolff3, Martin Bornhäuser4, Christian Thiede4, Herrad Baurmann5, Wolfgang Bethge6, York Hildebrandt1, Ulrike Bacher1, Boris Fehse1, Axel R. Zander1 and Nicolaus Kröger1,*

Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby1, Anita Badbaran1, Tatjana Zabelina1, Guido Kobbe2, Joachim Hahn3, Daniel Wolff3, Martin Bornhäuser4, Christian Thiede4, Herrad Baurmann5, Wolfgang Bethge6, York Hildebrandt1, Ulrike Bacher1, Boris Fehse1, Axel R. Zander1 and Nicolaus Kröger1,*

TKI Therapy and depression

sandy craine's picture
Submitted by sandy craine on Thu, 03/06/2010 - 12:20pm
Conclusion:
Depression is a common problem in oncology, with many possible causal factors, including disease progression, treatment-related toxicities, social issues, and fear about the possibility of death. Thus it is oftentimes difficult to ascertain a relationship between depression and drug exposure. However, a striking pattern emerges from this series of seven patients. All were coping well with their disease psychologically before imatinib/dasatinib therapy, yet developed profound depression during treatment, with many experiencing complete remission or improvement of symptoms after dose reduction or drug discontinuation. Three patients demonstrated significant suicidal ideation—a psychiatric emergency. Interestingly, two patients had relapse of depression after TKI rechallenge and one patient was randomly assigned to the treatment arm of a placebo-controlled trial.

Conclusion:

Depression is a common problem in oncology, with many possible causal factors, including disease progression, treatment-related toxicities, social issues, and fear about the possibility of death. Thus it is oftentimes difficult to ascertain a relationship between depression and drug exposure. However, a striking pattern emerges from this series of seven patients. All were coping well with their disease psychologically before imatinib/dasatinib therapy, yet developed profound depression during treatment, with many experiencing complete remission or improvement of symptoms after dose reduction or drug discontinuation. Three patients demonstrated significant suicidal ideation—a psychiatric emergency. Interestingly, two patients had relapse of depression after TKI rechallenge and one patient was randomly assigned to the treatment arm of a placebo-controlled trial.

mmm! this is an interesting hypothesis. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

sandy craine's picture
Submitted by sandy craine on Wed, 02/06/2010 - 6:07pm

 ABSTRACT 

Background: Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia – regardless ofthe significant reduction of disease burden during treatment – since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited.

 ABSTRACT 

Background: Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia – regardless ofthe significant reduction of disease burden during treatment – since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited.

Pages